Robert Lorne Hopfner - 07 Nov 2025 Form 4 Insider Report for Evommune, Inc.

Role: Director, 10%+ Owner
Signature: /s/ Gregory S. Moss, Attorney-in-Fact
Issuer symbol: EVMN on NYSE
Transactions as of: 07 Nov 2025
Net transactions value: $0
Form type: 4
Filing time: 12 Nov 2025, 16:19:43 UTC
Previous filing: 05 Nov 2025
Next filing: 22 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Hopfner Robert Lorne	Director, 10%+ Owner	C/O EVOMMUNE, INC., 1841 PAGE MILL ROAD, SUITE 100, PALO ALTO	/s/ Gregory S. Moss, Attorney-in-Fact	12 Nov 2025	0001551966

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EVMN	Common Stock	Conversion of derivative security		+3,026			3,026	07 Nov 2025	By Trust	F1, F2
transaction	EVMN	Common Stock	Conversion of derivative security		+1,441,032			1,441,032	07 Nov 2025	By NFLS Delta III Limited	F1, F3, F4, F5, F6
transaction	EVMN	Common Stock	Conversion of derivative security		+1,632,441			1,632,441	07 Nov 2025	By Pivotal bioVenture Partners Fund I, L.P.	F1, F3, F4, F5, F7
transaction	EVMN	Common Stock	Conversion of derivative security		+294,502			294,502	07 Nov 2025	By Pivotal bioVenture Partners Fund II, L.P.	F5, F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EVMN	Series Seed Preferred Stock	Conversion of derivative security		-25,790	-100%		0	07 Nov 2025	Common Stock	3,026		By Trust	F1, F2
transaction	EVMN	Series Seed Preferred Stock	Conversion of derivative security		-7,145,647	-100%		0	07 Nov 2025	Common Stock	838,886		By NFLS Delta III Limited	F1, F6
transaction	EVMN	Series Seed Preferred Stock	Conversion of derivative security		-3,572,816	-100%		0	07 Nov 2025	Common Stock	419,441		By Pivotal bioVenture Partners Fund I, L.P.	F1, F7
transaction	EVMN	Series A Preferred Stock	Conversion of derivative security		-2,582,243	-100%		0	07 Nov 2025	Common Stock	324,578		By NFLS Delta III Limited	F3, F6
transaction	EVMN	Series A Preferred Stock	Conversion of derivative security		-7,230,283	-100%		0	07 Nov 2025	Common Stock	908,821		By Pivotal bioVenture Partners Fund I, L.P.	F3, F7
transaction	EVMN	Series B Preferred Stock	Conversion of derivative security		-1,895,260	-100%		0	07 Nov 2025	Common Stock	240,756		By NFLS Delta III Limited	F4, F6
transaction	EVMN	Series B Preferred Stock	Conversion of derivative security		-2,104,740	-100%		0	07 Nov 2025	Common Stock	267,367		By Pivotal bioVenture Partners Fund I, L.P.	F4, F7
transaction	EVMN	Series C Preferred Stock	Conversion of derivative security		-313,571	-100%		0	07 Nov 2025	Common Stock	36,812		By NFLS Delta III Limited	F5, F6
transaction	EVMN	Series C Preferred Stock	Conversion of derivative security		-313,571	-100%		0	07 Nov 2025	Common Stock	36,812		By Pivotal bioVenture Partners Fund I, L.P.	F5, F7
transaction	EVMN	Series C Preferred Stock	Conversion of derivative security		-2,508,575	-100%		0	07 Nov 2025	Common Stock	294,502		By Pivotal bioVenture Partners Fund II, L.P.	F5, F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.
F2	The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
F3	Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date.
F4	Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.
F5	Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.
F6	Securities are directly held by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
F7	Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
F8	Securities are directly held by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II"). Pivotal bioVenture Partners Fund II G.P. Ltd,, the general partner of Pivotal II, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal II are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund II G.P. Ltd, who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.